A Standard Nomenclature for Referencing and Authentication of Pluripotent Stem Cells by Kurtz, Andreas et al.
University of Massachusetts Medical School 
eScholarship@UMMS 
Open Access Articles Open Access Publications by UMMS Authors 
2018-01-09 
A Standard Nomenclature for Referencing and Authentication of 
Pluripotent Stem Cells 
Andreas Kurtz 
Charité - Universitätsmedizin Berlin 
Et al. 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/oapubs 
 Part of the Cell Biology Commons, Cells Commons, Databases and Information Systems Commons, 
and the Laboratory and Basic Science Research Commons 
Repository Citation 
Kurtz A, Seltmann S, Smith KP. (2018). A Standard Nomenclature for Referencing and Authentication of 
Pluripotent Stem Cells. Open Access Articles. https://doi.org/10.1016/j.stemcr.2017.12.002. Retrieved 
from https://escholarship.umassmed.edu/oapubs/3371 
Creative Commons License 
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License. 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Open Access Articles 
by an authorized administrator of eScholarship@UMMS. For more information, please contact 
Lisa.Palmer@umassmed.edu. 
Stem Cell Reports
Perspective
A Standard Nomenclature for Referencing and Authentication of Pluripotent
Stem Cells
Andreas Kurtz,1,* Stefanie Seltmann,1,* Amos Bairoch,2 Marie-Sophie Bittner,1 Kevin Bruce,3
Amanda Capes-Davis,4 Laura Clarke,5 Jeremy M. Crook,6,7,8 Laurence Daheron,9 Johannes Dewender,1
Adam Faulconbridge,5 Wataru Fujibuchi,10 Alexander Gutteridge,11 Derek J. Hei,12 Yong-Ou Kim,13
Jung-Hyun Kim,13 Anja Kolb- Kokocinski,14 Fritz Lekschas,1 Geoffrey P. Lomax,15 Jeanne F. Loring,16
Tenneille Ludwig,17 Nancy Mah,1 Tohru Matsui,18 Robert Mu¨ller,1 Helen Parkinson,5 Michael Sheldon,19
Kelly Smith,20 Harald Stachelscheid,1,21 Glyn Stacey,22,23 Ian Streeter,5 Anna Veiga,24 and Ren-He Xu25
1Charite´ - Universita¨tsmedizin Berlin, Berlin-Brandenburg Center for Regenerative Therapies, Berlin 13353, Germany
2CALIPHO group, University of Geneva and Swiss Institute of Bioinformatics, 1 rue Michel-Servet, 1211 Geneva 4, Switzerland
3Roslin Cells Limited and EBiSC, Edinburgh BioQuarter, Edinburgh EH16 4UX, UK
4CellBank Australia, Children’s Medical Research Institute (CMRI), Wentworthville, NSW 2145, Australia
5European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Trust Genome Campus, Hinxton,
Cambridge CB10 1SD, UK
6ARC Centre of Excellence for Electromaterials Science, Intelligent Polymer Research Institute, AIIM Facility, Innovation Campus,
University of Wollongong, Squires Way, Fairy Meadow, NSW 2519, Australia
7Illawarra Health and Medical Research Institute, University of Wollongong, Wollongong, NSW 2522, Australia
8Department of Surgery, St Vincent’s Hospital, The University of Melbourne, Fitzroy, VIC 3065, Australia
9Harvard Stem Cell Institute, Cambridge, MA 02138, USA
10Center for iPS Research and Application (CiRA), Kyoto University, Kyoto 606-8507, Japan
11Pfizer, Neuroscience and Pain RU, Portway, Granta Park, Cambridge CB21 6GP, UK
12Waisman Biomanufacturing, Waisman Center, University of Wisconsin, 1500 Highland Avenue, Madison, WI 53705, USA
13Division of Intractable Diseases, Center for Biomedical Sciences, National Institute of Health and Korea Centers for Diseases Control and Prevention,
Chungcheongbuk-do 363-951, Republic of Korea
14Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SD, UK
15California Institute for Regenerative Medicine, Lake Merritt Plaza, 1999 Harrison Street STE 1650, Oakland, CA 94612, USA
16Center for Regenerative Medicine, Department of Chemical Physiology, The Scripps Research Institute, 10550 North Torrey Pines Road SP30-3021,
La Jolla, CA 92037, USA
17WiCell Research Institute (WiCell Stem Cell Bank), Madison, WI 53719, USA
18Keio University School of Medicine, the Center for Medical Genetics, 35 Shinanomachi, Shinjyuku-ku, Tokyo 160-8582, Japan
19Department of Genetics, Rutgers, The State University of New Jersey, Life Sciences Building, Piscataway, NJ 08854-8009, USA
20University of Massachusetts Medical School, International Stem Cell Registry, 55 Lake Avenue North, Worcester, MA 01655, USA
21Berlin Institute of Health, Stem Cell Core Unit, Berlin 13353, Germany
22National Institute for Biological Standards and Control a Centre of the MHRA, South Mimms, South Mimms, Hertfordshire EN6 3QG, UK
23International Stem Cell Banking Initiative, Barley, Hertfordshire EN6 3QG, UK
24Barcelona Stem Cell Bank, Center of Regenerative Medicine in Barcelona, 08908 Hospitalet de Llobregat, Barcelona, Spain
25Faculty of Health Sciences, University of Macau, Avenida da Universidade, Taipa, Macau, China
*Correspondence: andreas.kurtz@charite.de (A.K.), stefanie.seltmann@charite.de (S.S.)
https://doi.org/10.1016/j.stemcr.2017.12.002
Unambiguous cell line authentication is essential to avoid loss of
association between data and cells. The risk for loss of references in-
creases with the rapidity that new human pluripotent stem cell
(hPSC) lines are generated, exchanged, and implemented. Ideally,
a single name should be used as a generally applied reference for
each cell line to access and unify cell-related information across
publications, cell banks, cell registries, and databases and to ensure
scientific reproducibility. We discuss the needs and requirements
for such a unique identifier and implement a standard nomencla-
ture for hPSCs, which can be automatically generated and regis-
tered by the human pluripotent stem cell registry (hPSCreg). To
avoid ambiguities in PSC-line referencing, we strongly urge pub-
lishers to demand registration and use of the standard name
when publishing research based on hPSC lines.
Risks Associated with Lack of a Unique Identifier for
hPSC Lines
Although a nomenclature was previously proposed for hu-
man pluripotent stem cell (hPSC) lines (Luong et al., 2011),
this was only adopted by a few cell banks. Its widespread
acceptance was hindered by lack of a central registry, which
would be necessary to avoid name duplications, and thus
utility of the nomenclature was limited. In addition, it
was not possible to encode in the name relationships be-
tween lines, for example whether different lines derive
from the same donor; moreover, the proposed nomencla-
ture contained modules for optional information, such as
disease or patient number, which were poorly defined,
thereby hindering standardization. The low community
penetration of this first nomenclature proposal resulted
in reality in the continuing lack of a standard unique iden-
tifier or name. This coincides with an accelerating growth
of research and application areas for hPSCs, leading to
the establishment of many new lines, which are indepen-
dently named by an increasing number of autonomous
generators. The consequences of this development are
the generation of identical names for different lines and,
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conversely, the accumulation of synonyms. For example,
generic names such as iPS-1, iPS-WT, or ALS-1 are accumu-
lating (Luong et al., 2011), making cross-referencing
impossible. Conversely, CRL2429 fibroblasts from the
American Type Culture Collection or line BJ provided by
Stemgent have been used by many laboratories to generate
iPSC lines, each assigned with a different name suggestive
of unrelatedness. Furthermore, renaming of lines is com-
mon and occurs when hPSC banks and registries store cells
frommany providers, when names are altered with owner-
ship changes, or when lines with isogenic or other genetic
modifications are established. We found that 10.2% of
approximately 1,900 hPSC lines registered in the hPSC
registry (hPSCreg) (https://hpscreg.eu/https://hpscreg.eu)
have multiple synonyms, and 84.4% have at least one syn-
onym. In the Cellosaurus database (http://web.expasy.org/
cellosaurus/), 15.1% of the 6,252 listed hPSC lines have
multiple synonyms and 49.5% have at least one additional
synonym. For example, the hESC line WA09 has 10 syno-
nyms used in literature: H9, WA 09, WA9, H9.hESCs, H9
ESC, H9 hES, H9ES, GE09, WAe003-A, WICELLe003-A,
and WAe009-A. Consequently, cross-referencing becomes
progressively ambiguous. Moreover, the relationships be-
tween lines are not traceable as lines from the same donor,
such as different clones derived from source cells or genet-
ically modified sublines, become disconnected from their
parental lines (Table 1).
The resulting equivocal hPSC-line names throughout
different resources poses a cumulative long-term risk of
dissociation between lines and annotated data and their
further erroneous inheritance. Specifically, loss of associa-
tion between an hPSC line and its donor data poses risks
in phenotype-genotype association studies and further re-
duces reproducibility of experiments with already pheno-
typically variable hPSCs. An observable tendency is the
ad hoc establishment of ever more hPSC lines tailored for
a specific application in many individual laboratories
(McKernan and Watt, 2013; Kobold et al., 2015). This is
at least partially due to the difficulties of searching and
directly comparing existing cell lines across the many re-
sources and because of the intrinsic uncertainty with re-
gard to authenticity and identity of lines established else-
where. This trend is likely supported by the variable
standards applied for quality assessment, cell and donor
characterization, and consent and data formats applied
by different labs, which further diminish utility and
comparability of hPSC lines and, thus, scientific validation
of results. The current efforts to develop common charac-
terization and data standards are driven primarily by
hPSC databases and hPSC banking initiatives (Seltmann
et al., 2016; French et al., 2015). Success of these efforts
will be essential to increase comparability and trust in the
quality of the available hPSC lines.
Measures to Identify and Authenticate hPSC Lines
Aminimal set of measures will considerably improve iden-
tification and authentication of hPSC lines. These are
(1) the provision of a mandatory genetic identity profile
as annotation to each hPSC line and (2) the application
of a standardized name, which serves as a unique identifier
(UI). Genetic authenticity profiles such as short tandem re-
peats (STR) or SNP profiles authenticate donor and all
derived hPSC lines. However, it should be emphasized
that genotype information including STR, SNP, or human
leukocyte antigen patterns could be used to reveal donor
identity if combined with other personal information
Table 1. Most Common Risks Leading to Ambivalent and Wrong Cell Line Names due to Absence of a Standard hPSC Nomenclature
and Unique Identifier
Reason Risk Risk Mitigation
Independent use of identical primary source cell for reprogramming
(e.g., commercial provider of primary cells, time lapses between
donations [e.g., healthy young and diseased old donor, donation in
different labs by same donor])
high genetic profiling, preferentially by short tandem repeats (STR);
use of acronym identifying donor in unique identifier;
link unique identifier to STR profile
Distribution of line between labs and other resources such as banks
and registries, which rename according to internal nomenclatures
high establish unchangeable unique identifier; link other names
as synonym
Change of ownership with renaming very high establish unchangeable unique identifier; link different
owner’s name as synonym
Renaming after genetic modification of line (subclones, isogenic
lines, reporter lines)
high establish link to unique identifier in the name
Using generic lab-style names (iPSC-1, ALS-4) very high establish unchangeable unique identifier; link generic name
as synonym
Cell culture contamination with other lines and subsequent mix-up
and misauthentication
high genetic profiling, preferentially by STR
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(Isasi et al., 2014; Morrison et al., 2017). Hence, data access
policies that comply with the data protection provisions
stipulated by the donor’s informed consent are required.
These measures limit public access to genetic data. In addi-
tion, the application of different genetic profiling stan-
dards by different labs reduces comparability. Therefore,
utilization of standardized names must be enforced as the
second essential measure to ensure hPSC-line identity.
Such a UI, or name, will unmistakably connect cell line-
specific annotations from multiple datasets, including ge-
netic profiles, the literature, and reference databases. To
implement anUI, we propose tomodify the previously pro-
posed nomenclature for hPSCs (Luong et al., 2011) and
adapt the recommended nomenclature system of the Inter-
national Cell Line Authentication Committee (ICLAC)
(http://iclac.org/resources/cell-line-names/). The modified
nomenclature uses the previously proposed identifier for
cell source, cell line, and cell type and complements this
with codification of relatedness of a given hPSC line to its
origin and its genetically modified derivatives (Table 2).
An automated toolwas realized to create these standardized
hPSC names, which are available from a central registry.
Implementation of the hPSC Nomenclature in
hPSCreg
The automated tool is implemented in hPSCreg and is
accessible online as a manual data entry form (https://
hpscreg.eu/user/cell_line_name/create) or programmati-
cally using the RESTFull application programming inter-
face (API) (https://hpscreg.eu/about/naming-tool#api).
Upon entering the essential set of name elements (Table 2
and Supplemental Experimental Procedures), a standard-
ized name is automatically created and further manual
editing blocked. The name can be generated at any time
during or after hPSC-line generation. Once a standard
name is generated, it is locked and a printable quick-
response code containing the name is automatically pro-
vided. Pre-existing synonyms of established lines are linked
to the new standard name to avoid any loss of linkage to
familiar names such as WA09 or H9 (standard name
WAe009-A). Standard cell line names are centrally regis-
tered in the hPSCreg catalog. In addition, the names are
deposited in the cell line database Cellosaurus (http://
web.expasy.org/cellosaurus) and a BioSamples identifier
(http://www.ebi.ac.uk/biosamples/) is assigned to each
cell line subsequent to naming (Figure 1). To demonstrate
the utility of the naming tool, an application example
has been successfully implemented at the European Bank
of induced Pluripotent Stem Cells (EBiSC), which deposits
iPSC lines from multiple laboratories and generates the
standard name via hPSCreg (De Sousa et al., 2017).
For validation of names, a semantic uniform resource
locator (URL) for every registered and validated cell line
is provided. This simple yet semantically meaningful
system for information retrieval improves cell line identifi-
cation and reduces syntax ambiguities. The URLs are
persistent and will not change over time, allowing their
use as uniform resource identifiers in an application
Table 2. Nomenclature: Elements and Scheme
Name of Element No. of Digits Example Comments Maximal Possibilities
1 generator acronym 2–6 XXXXXX self-assigned code provided by the generator;
capital letters
321,272,380
2 cell line type 1 ‘‘e’’ or ‘‘i’’ e: ESC line >2
i: induced PSC line
3 donor ID 3 001 alphanumerical 3-digit code 46,655
4 clone number 2–3 A alphabetic capital letter preceded by hyphen 702
5 subclone or subline 0–3 1 alphanumerical 2-character code preceded
by hyphen
1,330
total characters 8–16 >87 3 109 cell lines per generator acronym
>28 3 1018 unique names
Structure and elements of the hPSC nomenclature. Five descriptive elements compose a cell line name. (1) An acronym, for example of the generator insti-
tution, laboratory, a registry, or a bank. (2) The cell type—other symbols are, for example, (p) for parthenogenic or (s) for somatic cell nuclear transfer PSC
lines. (3) A unique alphanumerical identifier. Depending on future needs, this could be extended to 4 digits (1,679,615 possible permutations). These first
three elements together form a unique identifier linking the line to a single origin or donor, or blastocyst in case of ESC. Element (4) identifies each cell line,
or clone, which was generated from the donor, and element (5) identifies genetically modified subclones or sublines derived from a given clone. The fixed
string of elements helps to detect and avoid syntactic naming errors. The nomenclature does not include any personal information that might compromise
the privacy and confidentiality of the donor, as recommended in ICLAC’s guidelines for cell line naming. Automated generation of an autonomous donor
identifier module as part of the name safeguards privacy even further. An example is provided in Table S1.
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ontology (Seltmann et al., 2016) (Supplemental Experi-
mental Procedures).
Referencing of hPSC Line-Associated Data
The amount and type of information that can be encoded
in a name is limited by the rather practical argument of
maintaining human readability and label compatibility.
A limit of 16 characters for a practicable hPSC name is
used here. Several useful but impractical proposals have
previously been made for encoding of disease and genetic
information in a standard name. Although these attributes
are of high interest in hPSC research, their integration as
elements of a standard nomenclature would pose multiple
obstacles. A disease is a potentially changing and complex
donor attribute as it may be a transient condition; e.g., it
may develop only after an hPSC line has been derived
and additionally, donors may have multiple diseases or
phenotypes or are mere carriers of a genetic disease risk
without expressing the disease phenotype. Moreover, dis-
ease codification is not harmonized despite the existence
of disease and phenotype vocabularies in diverse nomen-
clatures, taxonomies, and ontologies. As a result, diagnosis
and disease acronyms are often complex, which could
make the name unreadable, error prone, vague, and inoper-
able for computation. Similar issues arise with respect to
genetic modifications, which could for example include
karyotypes, SNPs, and transgenic modifications in isogenic
clones associated with complex gene nomenclatures.
Instead of overcrowding the name with complex infor-
mation, a more flexible approach is required to associate
attributes such as cell type of origin, disease, phenotype,
genetic background, and others. These annotations should
be linked by the unique cell line name andmade accessible
through directly connected databases such as hPSCreg
and can be further expanded through linked resources
such as BioSamples. The BioSamples database at the
European Bioinformatics Institute (EBI) (http://www.ebi.
ac.uk/biosamples/https://www.ebi.ac.uk/biosamples/) ag-
gregates information for reference samples such as cell
lines, donors, and projects for which data exist in one of
the assay databases such as ArrayExpress, the European
Nucleotide Archive, or the European Genotype-Phenome
Archives (Faulconbridge et al., 2014; Barrett et al., 2012).
Furthermore, the BioSample(s) databases at the EBI, the
National Center for Biological Information, and the DNA
DataBank of Japan are cross-referenced. Linking the stan-
dard hPSC-line name to BioSamples IDs thus provides the
information available in the BioSamples database, such as
donor-related clinical records, biological samples, genes,
and genotypes; BioSamples also models relationships
such as ‘‘derived from,’’ providing the option to widely
expand the information associated with the cell line
(Figure 1).
Open Tasks and Enforcement of the Nomenclature
Provision of a standard nomenclature to build a name and
UI is an important first step toward reducing risks in hPSC
research through misreferencing and misidentification.
According to the ISO/AWI 20387, an international stan-
dard on biobanks and biobanking, ‘‘unique identifier’’ is
defined as a code that is associated with a single entity
within a given system and demands a database or reference
of names or identifiers, which is provided in hPSCreg. The
nomenclature tool also adheres to the FAIR data guiding
principles, aimed at enhancing the reusability of data hold-
ings with specific emphasis on enhancing the ability ofma-
chines to automatically find and use the data, in addition
Figure 1. Naming Scheme for hPSC Lines
A donor is recruited and hPSC lines generated by diverse generators
x, y, . n or deposited in banks and registries, which submit the
essential name elements to hPSCreg to automatically generate a
standard name. A BioSamples ID for the line and the donor is
automatically provided in parallel for each cell line. The names and
BioSamples IDs are locked and registered in a catalog in the
hPSCreg database as well as in the Cellosaurus cell line database.
Historical lines with non-standard names are often used in hPSC
banks and registries. Registration of these lines in hPSCreg will
automatically provide a standard name and link it to the pre-ex-
isting names, which remain as synonyms.
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to supporting its reuse by individuals (Wilkinson et al.,
2016). The proposed nomenclature and RESTful API web
service for the generation of a standard name, together
with a central name registry, promote identification and ac-
curate referencing of cell lines and research data. Currently,
more than 300 of the hPSCreg registered lines only have
the standard name, indicating increasing acceptance,
which is also promoted through the International Stem
Cell Banking Initiative and EBiSC (De Sousa et al., 2017;
Kim et al., 2017).
As a key reference for reporting cells used to obtain
research data and for linking literature resources, standard-
ized names are analogous to providing accurate descrip-
tions of reagents, or genes used in experiments. Thus, use
of standard names in the materials and methods section
of any paper should always be enforced where hPSC lines
have been used to generate published data. Any subsequent
abbreviations should be clearly linked to the full cell line
name. Truncating cell line names for ongoing use causes
confusion in the scientific literature and should be avoided.
Moreover, as pre-existing old and familiar names will
persist in the literature, there may be confusion when the
standard name is introduced. Although this can be mini-
mized by generating names that maintain a visible associa-
tion to a well-known cell line inwidespread use (e.g.,WA09
will be named WAe009-A), this is not always possible. In
addition, the standard name is linked to the pre-existing
name(s), which are stored as synonyms in the registry
(e.g., WA09, H9 etc. become synonyms of WAe009-A). We
would like to emphasize that the cell lines can be searched
inhPSCreg by their synonyms, and the search resultswould
then output all lines with their UIs. Any data/information
associated with a name and all its synonyms are linked,
including Biosamples ID- and Cellosaurus entry-associated
data. Thus even if the pre-existing non-standard name will
continue to exist as a synonym, the associated information,
references, and data will be linked to the standard name in
the registry. This manual and semi-automated mining pro-
cess will help users to safely associate data with lines. How-
ever, because of past inconsistency, naming linking all true
synonymous lines and their pre-existing publications and
data will require an active process by users and journals
(e.g., in the formof an erratumor by addingmissing synon-
ymous names to the registry). The cell line generators bear
the primary responsibility of selecting an UI for their cell
lines; however, research institutions, funding agencies,
and journal editors should insist on rigorous cell line refer-
encing, authentication, and traceable annotation to ensure
that research data are reliable and reproducible. Journals
such as Stem Cell Research already require hPSCreg standard
nomenclature as reference.
Ambiguities of cell line names are not restricted to hPSC
lines and are a widespread problem in cancer cell lines.
However, a nomenclature for these cell types may require
different name elements. Notably, the ICLAC group puts
emphasis on tissue of origin as being part of a cell line’s
name, and this is highly relevant for many cell lines such
as those from tumors. Our proposed nomenclature scheme
and nomenclature tool can easily be adjusted to fit any spe-
cific cell type and accommodate other string elements, for
example tissue of origin or species. Some ambiguities such
as donor origin, however, cannot be completely eliminated
by using unique names, especially when these are not sys-
tematically applied.
Resolving these remaining ambiguities requires the use
of genetic identifiers such as STR or SNP profiles for authen-
tication (Dirks and Drexler, 2011, 2013). Provision of such
data for each line, and development of an STR/SNP
resource for PSC-line authentication, should thus become
a key future task, for example through using the associated
BioSamples IDs as links to STR resources (Ruitberg et al.,
2001). Referencing across these different data sources is
not yet possible but would provide a powerful instrument
for cell line authentication (Yu et al., 2015; Barrett et al.,
2012). Principally, a unique name or identifier and a ge-
netic profile are both essential elements to ensure that mis-
authentication of hPSC lines is controlled. A clear nomen-
clature and tool for generating the standardized name is a
first step and is now available. Use of these names should
be strictly enforced.
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